Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 67Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Solid Tumor 2Rectal Neoplasms 2Prostatic Neoplasms 2HER2-positive Breast Cancer 2Colonic Neoplasms 2Carcinoma, Ductal, Breast 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Neoplasms, Unknown Primary 1Metastatic HER2-Positive Breast Cancer 1Lung Neoplasms 1Her2-Positive Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Elderly Metastatic Breast Cancer Population 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Biliary Tract Neoplasms 1

Interventions

Trastuzumab 25Paclitaxel 22Cyclophosphamide 20Docetaxel 17Taxes 14Lapatinib 13Doxorubicin 13Radiotherapy 12Bevacizumab 11Capecitabine 10Tamoxifen 9Immunohistochemistry 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Filgrastim 8Carboplatin 8Vorinostat 6Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6Chemotherapy, Adjuvant 6Biopsy 6Peripheral Blood Stem Cell Transplantation 5Everolimus 5liposomal doxorubicin 4ixabepilone 4Vinorelbine 4Neoadjuvant Therapy 4Immunoenzyme Techniques 4Gene Expression Profiling 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms, Male × pertuzumab × Clear all
NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00301899 2012-03-08

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡